Inhibitors of BMP‐1/tolloid‐like proteinases: efficacy, selectivity and cellular toxicity

Inhibitors of BMP‐1/tolloid‐like proteinases: efficacy, selectivity and cellular toxicity
复制标题

BMPâ1/tolloidâlike 蛋白酶抑制剂:功效、选择性和细胞毒性

DOI:
10.1002/2211-5463.12540
复制
发表时间:
2021
期刊:
影响因子:
2.6
通讯作者:
Moali C
Moali C
中科院分区:
生物学4区
文献类型:
--
作者:
Talantikite M;Lécorché P;Beau F;Damour O;Becker-Pauly C;Dive V;Vadon-Le Goff S;Moali C

文献摘要

参考文献

相似文献

BMP-1/tolloid样蛋白酶与meprins和ovastacin一起属于人金属蛋白酶的astacin家族。它们代表了治疗或预防广泛疾病如纤维化疾病或癌症的有希望的靶点。然而,由于缺乏良好表征的抑制剂以及关于其选择性和体内效率的问题,其病理生理作用的研究仍然受到损害。作为确定功能研究中使用的合适工具的第一步,我们对已知影响人类astacins蛋白水解活性的七种分子进行了系统比较,包括三种异羟肟酸盐(FG-2575,UK 383,367,S33 A),蛋白质sizzled,一种新的次膦酸抑制剂(RXP-1001)和广谱蛋白酶抑制剂(GM 6001,actinonin)。它们的体外功效、细胞毒性和细胞培养物中的功效被彻底表征。我们发现这些分子显示出非常不同的效力和选择性特征,异羟肟酸FG-2575和sizzled蛋白是非常强大的BMP-1选择性抑制剂,而膦肽RXP-1001则是一种广谱的astacins抑制剂。因此,应根据研究目的仔细考虑其使用,以避免结果误解。
BMP‐1/tolloid‐like proteinases belong to the astacin family of human metalloproteinases, together with meprins and ovastacin. They represent promising targets to treat or prevent a wide range of diseases such as fibrotic disorders or cancer. However, the study of their pathophysiological roles is still impaired by the lack of well‐characterized inhibitors and the questions that remain regarding their selectivity andin vivoefficiency. As a first step towards the identification of suitable tools to be used in functional studies, we have undertaken a systematic comparison of seven molecules known to affect the proteolytic activity of human astacins including three hydroxamates (FG‐2575, UK383,367, S33A), the protein sizzled, a new phosphinic inhibitor (RXP‐1001) and broad‐spectrum protease inhibitors (GM6001, actinonin). Their efficacyin vitro, their cellular toxicity and efficacy in cell cultures were thoroughly characterized. We found that these molecules display very different potency and selectivity profiles, with hydroxamate FG‐2575 and the protein sizzled being very powerful and selective inhibitors of BMP‐1, whereas phosphinic peptide RXP‐1001 behaves as a broad‐spectrum inhibitor of astacins. Their use should therefore be carefully considered in agreement with the aim of the study to avoid result misinterpretation.
DOI: 10.1021/jm061010z
发表时间: 2007-07-26
影响因子: 7.3
作者:
Fish, Paul V.;Allan, Gillian A.;Whitlock, Gavin A.
通讯作者: Whitlock, Gavin A.
DOI: 10.1111/j.1743-6109.2006.00103.x
发表时间: 2006-03
影响因子: 2.9
作者:
R. Reid;J. Mogford;R. Butt;A. deGiorgio-Miller;Thomas A. Mustoe, MD, FACS
通讯作者: R. Reid;J. Mogford;R. Butt;A. deGiorgio-Miller;Thomas A. Mustoe, MD, FACS
哺乳动物类蛋白酶之间的多样性:寡聚化和非催化结构域影响活性和特异性
DOI: 10.3204/pubdb-2016-04634
发表时间: 2016
期刊: --
影响因子: --
作者:
Bayley C
通讯作者: Bayley C
DOI: 10.1016/j.mam.2008.08.002
发表时间: 2008-10
影响因子: 10.6
作者:
Sterchi, Erwin E.;Stoecker, Walter;Bond, Judith S.
通讯作者: Bond, Judith S.
DOI: 10.1016/j.matbio.2015.01.010
发表时间: 2015-05-01
期刊: MATRIX BIOLOGY
影响因子: 6.9
作者:
Prox, Johannes;Arnold, Philipp;Becker-Pauly, Christoph
通讯作者: Becker-Pauly, Christoph